Compare SUZ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUZ | ABVX |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | Brazil | France |
| Employees | N/A | 67 |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.7B |
| IPO Year | 2002 | N/A |
| Metric | SUZ | ABVX |
|---|---|---|
| Price | $8.36 | $129.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $131.31 |
| AVG Volume (30 Days) | ★ 2.8M | 885.7K |
| Earning Date | 05-11-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | $52.14 |
| Revenue Next Year | $13.57 | $4,132.27 |
| P/E Ratio | $5.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.11 | $5.70 |
| 52 Week High | $11.54 | $148.83 |
| Indicator | SUZ | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 62.16 |
| Support Level | $8.11 | $106.03 |
| Resistance Level | $9.66 | $138.49 |
| Average True Range (ATR) | 0.19 | 5.46 |
| MACD | 0.01 | 0.91 |
| Stochastic Oscillator | 27.11 | 92.97 |
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.